Why is Natera stock up 3.5% today?

Why is Natera stock up 3.5% today?
Natera surges 3.51% today on news

Natera Inc (NTRA) jumped 3.51% after Japan's regulatory authority approved its Signatera test as a companion diagnostic for muscle-invasive bladder cancer, creating a new growth opportunity for the company. The move is supported by strong bullish momentum, with the stock trading well above all major moving averages and momentum signals reinforcing upward conviction.

NTRA price prediction
24H 0.24%
$319.84
48H 0.59%
$320.97
7D 1.6%
$324.2
1M -25.75%
$236.91
3M -14.2%
$273.78
6M -23.81%
$243.12
12M 53.02%
$488.28
Current price: $319.09 -4.1800 1.29%
Closed 11/13
Daily range 312.08 Arrow from to Icon 324.98
Weekly range 306.58 Arrow from to Icon 326.92
Loading...

Highlights

  • Natera secured Japanese regulatory approval for its Signatera test in muscle-invasive bladder cancer, targeting a market launch in early 2027.
  • Natera reported a 37.7% year-over-year revenue increase to $752.75 million and raised 2026 guidance.
  • Shares of Natera trade in a strong uptrend with robust bullish technical signals, expected to consolidate within a $386.66 to $422.33 range.

Japanese entry and director share sale shape market outlook

Natera received approval from Japan's Pharmaceuticals and Medical Devices Agency for the Signatera test in muscle-invasive bladder cancer, unlocking entry into the Japanese market with a launch planned for the first half of 2027. In the latest quarter, Natera reported a 37.7% revenue increase to $752.75 million and raised its guidance for 2026. Director Jonathan Sheena also filed to sell 21,064 shares valued at approximately $8.16 million in September 2026.

Anton Kharitonov, expert at Traders Union, sees the recent price jump in Natera as driven by strong news momentum and technical overextension. He notes that while regulatory approval in Japan creates opportunity, rising insider selling and extremely overbought oscillators introduce elevated downside risk. The expert highlights that the upward impulse is supported by bullish moving averages, but the current RSI and CCI indicate the stock may be overheating. He remains wary of speculative buying at extended valuations and persistent intraday volatility. "Traders should be cautious — overbought readings and insider selling point to a possible near-term correction despite the bullish narrative," Kharitonov warns.
Viktoras Karapetjanc, expert at Traders Union, highlights the significance of Japan's regulatory approval for Natera as a transformative growth catalyst. He believes robust revenue growth, higher 2026 guidance, and institutional confidence following the news underpin a bullish structure. Karapetjanc sees the global healthcare trend and new market entry setting the stage for further expansion. He emphasizes that momentum remains strong with favorable probabilities for continued gains. "The bullish structure remains intact — Natera’s international push and solid financials make further growth likely in this market cycle," says Karapetjanc.
Parshwa Turakhiya, analyst, observes Natera sustaining a powerful short-term uptrend with buyers firmly in control. He sees intraday volatility at 5.16% as an extra catalyst for tactical setups, especially given persistent strength toward session highs. Turakhiya notes that several momentum indicators flashing overbought suggest a possible pause before the next directional move. He remains focused on price action near the $394.86 floor and $408.51 breakout zone for actionable scenarios. "Current sentiment favors bulls, but I would watch those levels closely for quick reaction trades as volatility remains elevated," Turakhiya states.
Natera Inc asset chart
Natera Inc price dynamics. Source: TradingView.

Technical strength as overbought signals flag reversal risk

Natera is trading well above its 20-day, 50-day, and 200-day moving averages ($343.15, $311.03, and $242.87 respectively), reinforcing bullish momentum across all timeframes. The sustained uptrend is further supported by the Ichimoku Kijun baseline ($352.62) and the bullish MA-50 vs MA-200 alignment, with the near-term ceiling at $408.51 and support at the $394.86 near-term floor. Momentum gauges remain robust: the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) both give buy signals, reflecting strong directional conviction. The Relative Strength Index (RSI) has surged into overbought territory at 79.64, confirmed by similar extreme readings on the Stochastic RSI and Commodity Channel Index (CCI). Bull/Bear Power (BBP) shows buyers dominating intraday action, but its overbought reading warns of potential exhaustion. The Awesome Oscillator also backs the prevailing bullish tone. Natera climbed $13.70 or 3.51% today after opening with a slight downside gap, now sitting near session highs as intraday volatility stands at 5.16%. The session indicates persistent strength toward the highs in line with momentum signals, although several oscillators flag a potential short-term overbought pause.

Earlier, analysts noted that Natera’s record revenue growth and raised guidance reflected sustained bullish momentum driven by its oncology segment. The latest approval of Signatera in Japan adds a new international growth catalyst, and traders should monitor whether the stock maintains consolidation above the $394.86 support amid heightened volatility.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.